News

The Parkinson’s Foundation is bringing Allied Team Training for Parkinson’s (ATTP), its signature professional education program, to Iowa City, Iowa, on March 27-30. The program is intended to help medical professionals from diverse disciplines learn the best techniques in Parkinson’s care.  Using a dynamic team-based approach,…

A specific magnetic resonance imaging (MRI) measure can accurately predict the development of eye movement abnormalities, helping to identify patients who develop progressive supranuclear palsy with parkinsonism (PSP-P) after an initial diagnosis of Parkinson’s, a study shows. The study, “Refining initial diagnosis of Parkinson’s disease after follow‐up:…

ProMIS Neurosciences has identified several antibody candidates that specifically target the toxic forms of alpha-synuclein, a key component of Lewy bodies that underlie the development of Parkinson’s disease. In vitro (in the lab) studies have shown that ProMIS’s antibody candidates for Parkinson’s disease have a high specificity for toxic forms of…

Chronic sleep restriction alters movement, worsens cognitive dysfunction and induces changes in the levels of several amino acids — the building blocks of proteins — and other markers in rats with Parkinson’s, according to a new study. According to researchers, these findings could enable the use of biomarkers to…

Levodopa (L-DOPA) therapy is neuroprotective and prevents age-related iron accumulation in the substantia nigra, a brain region involved in Parkinson’s disease. The study with that finding, “L-DOPA modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson’s disease,” was published in…

Vitamin A, or retinol, given as an oral supplement did not prevent the loss of dopamine-producing neurons or lessen motor deficits in a rat model of Parkinson’s, a study reports. Results also showed that retinol lowered levels of inflammatory markers in the blood and did not cause oxidative damage in…

These days, people with Parkinson’s disease tend to ask their doctors more questions about cannabis than any other subject; yet, few physicians have adequate answers for them. So says a new survey announced by the Parkinson’s Foundation, which plans a conference on that subject next month in Denver. The…

Upon breaking down two decades of research about how the gut affects the brain in Parkinson’s disease, a vision for studying the gut-brain connection for the next two decades has been laid out in a review article published in the Journal of Parkinson’s Disease. Specifically, the…

A common depression treatment called agomelatine worsens Parkinson’s-related loss of dopamine-producing neurons, motor dysfunction, and protein oxidation, according to research in rats. The study with that finding, “Effects of Agomelatine in Rotenone-induced Parkinson’s Disease in Rats,” was published in the journal Neuroscience Letters. Neuroinflammation, oxidative…

Patients with hypertension may be at a higher risk for Parkinson’s disease, according to a review of population-based studies. The review, “Association between Hypertension and the Risk of Parkinson’s Disease: A Meta-Analysis of Analytical Studies,” appeared in the journal Neuroepidemiology. Hypertension may cause damage…